Related Experiment Video

Updated: Feb 6, 2026

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.7K

The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results

Luciano Quaranta1, Elena Biagioli2, Ivano Riva3

  • 1Department of Medical and Surgical Specialties, Section of Ophthalmology, University of Brescia, Brescia.

Journal of Glaucoma
|August 11, 2018
PubMed

Insights

Latanoprost and dorzolamide combination therapy is safe and effective for lowering intraocular pressure in pediatric glaucoma patients post-surgery. Early disease presentation was linked to non-response to these treatments.

Area of Science:

  • Ophthalmology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Pediatric glaucoma management often requires multifaceted treatment strategies.
  • Postsurgical intraocular pressure (IOP) control is crucial in preventing disease progression.
  • Identifying effective pharmacological interventions for partially responsive cases is essential.

Purpose of the Study:

  • To evaluate the efficacy and safety of latanoprost and dorzolamide in children with primary pediatric glaucoma partially responsive to surgery.
  • To determine the optimal treatment strategy involving latanoprost monotherapy, latanoprost/dorzolamide combination, or dorzolamide monotherapy.

Main Methods:

  • A cohort of 37 children (61 eyes) with postsurgical IOP between 22-26 mmHg was analyzed.
  • Patients received latanoprost monotherapy, with options to add dorzolamide or switch to dorzolamide monotherapy based on IOP response.
  • Treatment efficacy was assessed over 3 years, with the primary endpoint being the percentage of responders.

Main Results:

  • 76.7% of eyes (33/43) were responders to pharmacological treatment.
  • Latanoprost monotherapy showed a high response rate (19 eyes), followed by the combination (11 eyes) and dorzolamide monotherapy (3 eyes).
  • Treatment efficacy was inversely correlated with central corneal thickness and age at surgery; no adverse events led to withdrawal.

Conclusions:

  • Latanoprost, alone or combined with dorzolamide, offers a safe and effective approach to lower intraocular pressure in pediatric glaucoma patients post-surgery.
  • Patients with early disease presentation were more likely to be non-responders to the tested pharmacological strategies.
  • The findings support the use of these medications in managing refractory pediatric glaucoma cases.
Abstract

More Related Videos

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.4K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.9K

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.4K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
314
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
237